BioLineRx Initiates Phase 1/2a Study for GLIX1 in Glioblastoma, Targeting H1 2027 Data Readout

summarizeSummary

BioLineRx announced the initiation of a Phase 1/2a clinical trial for GLIX1 in glioblastoma, detailing the study design, key investigators, and an anticipated data readout in the first half of 2027.

check_boxKey Events

• Phase 1/2a GLIX1 Trial Initiated

  BioLineRx has commenced a first-in-human Phase 1/2a study (NCT07464925) for GLIX1, an oral small molecule targeting DNA damage response in recurrent and progressive glioblastoma (GBM) and other high-grade glioma.

• Key Investigators and Centers

  The study will involve renowned academic centers, including NYU Langone Health, Northwestern University (led by Dr. Roger Stupp), and Moffit Cancer Center, bringing significant expertise to the trial.

• Preclinical Efficacy and Safety

  GLIX1 demonstrated potent anti-tumor activity in GBM models, excellent blood-brain barrier penetration, and a favorable safety profile in preclinical studies.

• Anticipated Data Readout

  Initial data from the Phase 1 part of the trial, focusing on safety, PK/PD, and preliminary efficacy, are expected in the first half of 2027.

auto_awesomeAnalysis

This filing provides crucial details regarding the initiation of a Phase 1/2a clinical trial for GLIX1, a first-in-class treatment for glioblastoma. For a clinical-stage biopharmaceutical company facing a "going concern" warning (as disclosed in its recent 20-F), advancing a lead asset into human trials is a critical step towards validating its pipeline and securing its future. The involvement of renowned investigators and the specific timeline for initial data in H1 2027 offer important milestones for investors to monitor. This progress is vital for the company's long-term viability.